Virender Kumar, PhD

Research Assistant ProfessorVirender Kumar

Department of Pharmaceutical Sciences
University of Nebraska Medical Center
985800 Nebraska Medical Center
DRC-1, 1010
Omaha, NE 68198-6025

Teaching Activities:
Dr. Kumar is currently pursuing teaching opportunities in the areas of Pharmaceutics and Pharmacokinetics.

Research Activities/Interests:
Dr. Kumar’s research focuses on investigating the codelivery of therapeutic agents and miRNAs and targeted nanotechnology-based formulations for the treatment of cancer and liver fibrosis. This work involves the polymer synthesis and characterization, subcellular trafficking studies, toxicological studies, and small animal imaging and pharmacokinetics.

Another area of interest of Dr. Kumar is the development and characterization of inhalation formulations for treatment of pulmonary diseases.

Recent Publications:

Journal articles

  1. Xin X, Kumar V, Lin F, Kumar V, Bhattarai Rajan, Bhatt V, Tan C, and. Mahato RI, Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. Science Advances, 2020: Vol. 6, no. 46.
  2. Bhattarai RS, Kumar V, Romanova S, Bariwal J, Chen H, Deng S, Bhatt VR, Bronich T, Li W, Mahato RI. Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. J Control Release. 2020 Sep 30:S0168-3659(20)30568-X.
  3. Wang Q, Kumar V, Lin F, Sethi B, Coulter DW, McGuire TR, Mahato RI. ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice. J Control Release. 2020 Jul 10;323:463-474.
  4. Kumar V, Bariwal J, Narang AS, Tso J, Cheong J, Mahato RI. Functional similarity of modified cascade impactor to deposit drug particles on cells. Int J Pharm. 2020 Jun 15;583:119404.
  5. Kumar V, Dong Y, Kumar V, Almawash S, Mahato RI. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis. Theranostics. 2019 Oct 12;9(25):7537-7555.
  6. Bariwal J, Kumar V, Chen H, Bhattarai RS, Peng Y, Li W, Mahato RI. Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. J Control Release. 2019 Sep 10;309:231-243.
  7. Kumar V, Kumar V, Luo J, Mahato RI. Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis. Mol Ther. 2018 Dec 5;26(12):2798-2811.
  8. Kumar V, Mundra V, Peng Y, Wang Y, Tan C, Mahato RI. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Theranostics. 2018 Jul 5;8(15):4033-4049.
  9. Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Cancer Lett. 2017 Aug 28;402:1-8.
  10. Kumar V, Chaudhary AK, Dong Y, Zhong HA, Mondal G, Lin F, Kumar V, Mahato RI. Design, Synthesis, and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Sci Rep. 2017 May 10;7(1):1665.

Book chapters

  1. Kumar V, Wen D, Mahato RI, Non-Viral Delivery of Nucleic Acid Complexes. Comprehensive Biomaterials II 2017 May 4, 506–526.